Close Menu

NEW YORK – Sema4 said on Wednesday that it has signed an agreement to merge with CM Life Sciences, a special purpose acquisition company (SPAC) sponsored by affiliates of Casdin Capital and Corvex Management, with the ultimate purpose of becoming publicly traded through the company's position on the Nasdaq Global Market.

Once the transaction is complete, expected in the second quarter, CM Life Sciences will be renamed and its common stock will be listed on the Nasdaq under a name and ticker symbol that has yet to be announced.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.